These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22299825)

  • 1. Optimisation of DMPK by the inhaled route: challenges and approaches.
    Cooper AE; Ferguson D; Grime K
    Curr Drug Metab; 2012 May; 13(4):457-73. PubMed ID: 22299825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs.
    Matera MG; Calzetta L; Ora J; Rogliani P; Cazzola M
    Expert Opin Drug Deliv; 2021 Jul; 18(7):891-906. PubMed ID: 33412922
    [No Abstract]   [Full Text] [Related]  

  • 3. Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties.
    Tolman JA; Williams RO
    Drug Dev Ind Pharm; 2010 Jan; 36(1):1-30. PubMed ID: 19640248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery.
    Sakagami M
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1030-60. PubMed ID: 17010473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in inhaled product development and opportunities for open innovation.
    Forbes B; Asgharian B; Dailey LA; Ferguson D; Gerde P; Gumbleton M; Gustavsson L; Hardy C; Hassall D; Jones R; Lock R; Maas J; McGovern T; Pitcairn GR; Somers G; Wolff RK
    Adv Drug Deliv Rev; 2011; 63(1-2):69-87. PubMed ID: 21144875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of inhaled drugs.
    Lipworth BJ
    Br J Clin Pharmacol; 1996 Dec; 42(6):697-705. PubMed ID: 8971424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery.
    Hu X; Yang FF; Liao YH
    Curr Pharm Des; 2016; 22(17):2532-48. PubMed ID: 26818873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of efficacious inhalation lung doses via the use of in silico lung retention quantitative structure-activity relationship models and in vitro potency screens.
    Cooper A; Potter T; Luker T
    Drug Metab Dispos; 2010 Dec; 38(12):2218-25. PubMed ID: 20823295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaling medicines: delivering drugs to the body through the lungs.
    Patton JS; Byron PR
    Nat Rev Drug Discov; 2007 Jan; 6(1):67-74. PubMed ID: 17195033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals.
    Nahar K; Gupta N; Gauvin R; Absar S; Patel B; Gupta V; Khademhosseini A; Ahsan F
    Eur J Pharm Sci; 2013 Aug; 49(5):805-18. PubMed ID: 23797056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy.
    Mukker JK; Singh RS; Derendorf H
    Adv Drug Deliv Rev; 2015 May; 85():57-64. PubMed ID: 25770775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery Technologies for Orally Inhaled Products: an Update.
    Moon C; Smyth HDC; Watts AB; Williams RO
    AAPS PharmSciTech; 2019 Feb; 20(3):117. PubMed ID: 30783904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current approaches to the discovery of novel inhaled medicines.
    Strong P; Ito K; Murray J; Rapeport G
    Drug Discov Today; 2018 Oct; 23(10):1705-1717. PubMed ID: 29775668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.
    Borghardt JM; Weber B; Staab A; Kloft C
    AAPS J; 2015 Jul; 17(4):853-70. PubMed ID: 25845315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary Formulation Development for Inhaled Pharmaceuticals.
    Sou T; Bergström CAS
    J Pharm Sci; 2021 Jan; 110(1):66-86. PubMed ID: 32916138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benchmarking of Human Dose Prediction for Inhaled Medicines from Preclinical In Vivo Data.
    Ericsson T; Fridén M; Kärrman-Mårdh C; Dainty I; Grime K
    Pharm Res; 2017 Dec; 34(12):2557-2567. PubMed ID: 28685298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Affecting Drug Exposure after Inhalation.
    Nováková A; Šíma M; Slanař O
    Prague Med Rep; 2022; 123(3):129-139. PubMed ID: 36107443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhalation Biopharmaceutics: Progress Towards Comprehending the Fate of Inhaled Medicines.
    Ehrhardt C
    Pharm Res; 2017 Dec; 34(12):2451-2453. PubMed ID: 29147818
    [No Abstract]   [Full Text] [Related]  

  • 19. Models of deposition, pharmacokinetics, and intersubject variability in respiratory drug delivery.
    Martin AR; Moore CP; Finlay WH
    Expert Opin Drug Deliv; 2018 Dec; 15(12):1175-1188. PubMed ID: 30388902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs.
    Kukut Hatipoglu M; Hickey AJ; Garcia-Contreras L
    Int J Pharm; 2018 Oct; 549(1-2):306-316. PubMed ID: 30077761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.